(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three most active and biggest winners today are Tornier N.V., TherapeuticsMD, and Technical Communications Corporation.

Rank Financial Asset Price Change Updated (EST)
1 Tornier N.V. (TRNX) 0.00 120% 2022-08-01 04:43:15
2 TherapeuticsMD (TXMD) 8.59 37.88% 2022-08-01 14:50:56
3 Technical Communications Corporation (TCCO) 1.25 17.92% 2022-08-01 01:14:05
4 Carrols Restaurant Group (TAST) 2.49 15.28% 2022-08-01 00:23:15
5 Tecogen (TGEN) 1.35 12.97% 2022-08-01 02:23:14
6 Celsius Holdings (CELH) 99.80 12.19% 2022-08-01 14:48:21
7 Roku (ROKU) 71.71 9.45% 2022-08-01 14:50:20
8 Groupon (GRPN) 11.50 8.49% 2022-08-01 14:58:31
9 Sarepta Therapeutics (SRPT) 92.95 8.17% 2022-07-31 21:23:15
10 Nautilus (NLS) 1.87 7.47% 2022-08-01 14:47:21

The three most active and biggest losers today are Tonix Pharmaceuticals Holding Corp., 21Vianet Group, and Royal Caribbean Cruises.

Rank Financial Asset Price Change Updated (EST)
1 Tonix Pharmaceuticals Holding Corp. (TNXP) 1.68 -10.16% 2022-08-01 03:15:05
2 21Vianet Group (VNET) 4.75 -8.04% 2022-08-01 13:10:08
3 Royal Caribbean Cruises (RCL) 35.67 -7.85% 2022-08-01 14:57:36
4 Ultra Clean Holdings (UCTT) 33.60 -6.9% 2022-08-01 07:41:15
5 Travelzoo (TZOO) 5.09 -6.43% 2022-08-01 07:18:04
6 TG Therapeutics (TGTX) 5.99 -6.26% 2022-08-01 03:07:08
7 Canaan (CAN) 3.69 -6.11% 2022-08-01 14:48:18
8 Tilray (TLRY) 3.43 -6.03% 2022-08-01 14:50:44
9 Trevena (TRVN) 0.25 -5.67% 2022-08-01 05:08:05
10 Marathon (MARA) 12.26 -5.6% 2022-08-01 14:59:42

Most Active Winners today

1. Tornier N.V. (TRNX) – 120%

Taronis Technologies, Inc. is a technology-based firm that focuses on the challenges of natural resources, with a primary focus on the United States. MagneGas is a hydrogen-based, synthetic fuel used to replace acetylene or other natural gas-derived fuels for metal cutting. The company also offers Plasma Arc flow system for MagneGas production or water sterilization. The company also licenses its plasma arc technology, which is used for liquid waste processing and gasification. The company distributes MagneGas gas, as well as other supplies and gases through retailers. In January 2019, Taronis Technologies, Inc. was established. The previous name of the company was MagneGas Applied Technology Solutions, Inc. Taronis Technologies, Inc. is located in Peoria, Arizona.

NASDAQ ended the session with Tornier N.V. rising 120% to $0.00 on Monday, following the last session’s upward trend. NASDAQ dropped 0.18% to $12,368.98, after three sequential sessions in a row of gains, on what was a somewhat bearish trend trading session today.

Volume

Today’s last reported volume for Tornier N.V. is 158202 which is 79.59% above its average volume of 88086.

Tornier N.V.’s last close was $0.00, 95.51% below its 52-week high of $0.02.

Tornier N.V.’s Sales

Tornier N.V.’s sales growth is 148.6% for the present quarter and 126% for the next.

Tornier N.V.’s Revenue

Year-on-year quarterly revenue growth grew by 104.7%, now sitting on 19.17M for the twelve trailing months.

Tornier N.V.’s Moving Average

Tornier N.V.’s value is below its 50-day moving average of $0.00 and under its 200-day moving average of $0.00.

More news about Tornier N.V..

2. TherapeuticsMD (TXMD) – 37.88%

TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17AY-estradiol, progesterone, for moderate to severe vasomotor symptoms. TX-015HR is a transdermal patch candidate that contains progesterone and estradiol. TX-009HR is the company’s clinical product. It contains an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins under the vitaTrue and vitaMedMD brands. It sells prescription hormone therapy drugs and prenatal vitamins to both wholesale and retail pharmacie distributors. TherapeuticsMD, Inc., is located in Boca Raton, Florida.

NASDAQ ended the session with TherapeuticsMD rising 37.88% to $8.59 on Monday, after four sequential sessions in a row of gains. NASDAQ dropped 0.18% to $12,368.98, after three sequential sessions in a row of gains, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for TherapeuticsMD is 6173040 which is 331.89% above its average volume of 1429290.

TherapeuticsMD’s last close was $6.23, 88.25% below its 52-week high of $53.00.

TherapeuticsMD’s Sales

TherapeuticsMD’s sales growth is a negative 9.6% for the current quarter and 24.1% for the next. The company’s growth estimates for the ongoing quarter and the next is 27.3% and 50%, respectively.

TherapeuticsMD’s Revenue

Year-on-year quarterly revenue growth declined by 17.3%, now sitting on 86.95M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

TherapeuticsMD’s stock is considered to be oversold (<=20).

TherapeuticsMD’s Stock Yearly Top and Bottom Value

TherapeuticsMD’s stock is valued at $8.59 at 17:32 EST, way below its 52-week high of $53.00 and way above its 52-week low of $1.99.

TherapeuticsMD’s Moving Average

TherapeuticsMD’s worth is way above its 50-day moving average of $7.30 and way below its 200-day moving average of $17.44.

More news about TherapeuticsMD.

3. Technical Communications Corporation (TCCO) – 17.92%

Technical Communications Corporation is involved in designing, developing, manufacturing, distribution, marketing and selling communications security systems and devices worldwide. It mainly provides voice, data, fax and video networks. CSD3324 SE secure telephone, data and fax system; CSD3324 SP telephone system and fax system; DSD 72A–SP military bulk encryption system; DSP 9000 radio encrypted system. Also, the HSE 6600 squad radio headset, telephone encryptor to public safety, special operations and land mobile radio applications and military applications. It also offers network security systems that include network encryption systems, centralized keys, device management, for SONET/SDH and frame relay networks, to protect data as it travels from one local area network to another and over large area networks. It also offers secured office systems such as the CSD4100 executive secure phone and CipherTalk8500 internet protocol (IP-based) secure wireless telephone. Its products protect confidential communications among radios, landline phones, mobile phones and facsimile devices, as well as data network equipment over wires and fiber optic cables. It also offers technology development and research funding. It serves many markets including domestic and foreign governmental agencies as well as law enforcement and military authorities, telecommunications providers, financial institutions and multinational businesses that require protection of mission critical information. The company sells direct to original equipment producers, customers and value-added resellers through its own sales force. It also has domestic and international reps, consultants and distributors. Technical Communications Corporation was established in Concord, Massachusetts in 1961.

NASDAQ ended the session with Technical Communications Corporation rising 17.92% to $1.25 on Monday, following the last session’s upward trend. NASDAQ dropped 0.18% to $12,368.98, after three consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Volume

Today’s last reported volume for Technical Communications Corporation is 230 which is 81.57% below its average volume of 1248.

Technical Communications Corporation’s last close was $1.25, 63.13% below its 52-week high of $3.39.

Technical Communications Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 8.3%, now sitting on 2.07M for the twelve trailing months.

Technical Communications Corporation’s Stock Yearly Top and Bottom Value

Technical Communications Corporation’s stock is valued at $1.25 at 17:32 EST, way below its 52-week high of $3.39 and way above its 52-week low of $1.01.

Technical Communications Corporation’s Moving Average

Technical Communications Corporation’s value is below its 50-day moving average of $1.35 and way below its 200-day moving average of $1.75.

More news about Technical Communications Corporation.

4. Carrols Restaurant Group (TAST) – 15.28%

Through its subsidiaries, Carrols Restaurant Group, Inc. operates in the United States as a restaurant business. It is a Burger King franchisee. It had 1,009 Burger King locations in 23 Northeastern and Midwestern states, Southcentral and Southcentral states, as well 65 Popeyes restaurants within seven Southeastern States. It was established in 1960 in Syracuse, New York.

NASDAQ ended the session with Carrols Restaurant Group jumping 15.28% to $2.49 on Monday, after three successive sessions in a row of gains. NASDAQ dropped 0.18% to $12,368.98, after three successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for Carrols Restaurant Group is 526595 which is 46.56% above its average volume of 359291.

Carrols Restaurant Group’s last close was $2.49, 52.93% below its 52-week high of $5.29.

Carrols Restaurant Group’s Sales

Carrols Restaurant Group’s sales growth is 2.8% for the current quarter and 5.3% for the next.

Carrols Restaurant Group’s Revenue

Year-on-year quarterly revenue growth declined by 1%, now sitting on 1.65B for the twelve trailing months.

Carrols Restaurant Group’s Stock Yearly Top and Bottom Value

Carrols Restaurant Group’s stock is valued at $2.49 at 17:32 EST, way under its 52-week high of $5.29 and way above its 52-week low of $1.28.

Carrols Restaurant Group’s Moving Average

Carrols Restaurant Group’s worth is way above its 50-day moving average of $2.02 and below its 200-day moving average of $2.51.

More news about Carrols Restaurant Group.

5. Tecogen (TGEN) – 12.97%

Tecogen Inc. develops, produces, markets and maintains commercial and industrial cogeneration systems. These systems produce a combination of hot water and electricity for commercial, residential, industrial, industrial, and recreational use throughout the United States as well as internationally. The company operates under two main segments: Products and Services and Energy Production. InVerde e+ is a cogeneration product which produces electricity and hotwater; TECOGEN systems to produce hot water; TECOCHILL air conditioning and refrigeration chillers; Tecofrost engine-driven compressors for refrigeration; water heaters under Ilios and emissions control technology under Ultera. The company offers long-term maintenance agreements, parts sales and turnkey installations services via a network that includes eleven service centers located in California, California’s Midwest, Northeast and Southeast as well as Ontario Canada. The company also installs, manages and operates distributed generation and energy systems. The company serves hospitals, nursing homes, schools, medical centers, colleges, universities and hotels. It was founded in 2000, and its headquarters is in Waltham Massachusetts.

NASDAQ ended the session with Tecogen jumping 12.97% to $1.35 on Monday while NASDAQ fell 0.18% to $12,368.98.

Volume

Today’s last reported volume for Tecogen is 57244 which is 456.3% above its average volume of 10290.

Tecogen’s last close was $1.35, 36.02% under its 52-week high of $2.11.

The company’s growth estimates for the ongoing quarter and the next is a negative 100% and a negative 116.7%, respectively.

Tecogen’s Revenue

Year-on-year quarterly revenue growth grew by 26.9%, now sitting on 24.4M for the twelve trailing months.

Tecogen’s Stock Yearly Top and Bottom Value

Tecogen’s stock is valued at $1.35 at 17:32 EST, way below its 52-week high of $2.11 and way higher than its 52-week low of $0.70.

Tecogen’s Moving Average

Tecogen’s value is above its 50-day moving average of $1.28 and below its 200-day moving average of $1.39.

More news about Tecogen.

6. Celsius Holdings (CELH) – 12.19%

Celsius Holdings, Inc. markets, distributes, sells and promotes functional, calorie-burning, fitness drinks in the United States as well as internationally. It offers a variety of beverages, such as carbonated orange and wild berry, cola and grape, kiwi guava and watermelon. Celsius Heat is a nutritional supplement that contains carbonated flavorings such as orange jack’d and blueberry pomegranate. Blueberry pomegranate. strawberry dragonfruit. tangerine grapefruit. It distributes products via direct-store distribution distributors as well as retailers that include supermarkets and convenience stores as well as drug and nutritional stores and mass merchants. In January 2007, Celsius Holdings, Inc. was established. Celsius Holdings, Inc., was established in 2004. It is located in Boca Raton, Florida.

NASDAQ ended the session with Celsius Holdings rising 12.19% to $99.80 on Monday while NASDAQ dropped 0.18% to $12,368.98.

Volume

Today’s last reported volume for Celsius Holdings is 4222170 which is 279.12% above its average volume of 1113660.

Celsius Holdings’s last close was $88.96, 19.29% under its 52-week high of $110.22.

Celsius Holdings’s Sales

Celsius Holdings’s sales growth is 117.7% for the present quarter and 64.5% for the next. The company’s growth estimates for the current quarter and the next is 20% and 233.3%, respectively.

Celsius Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 192.3%, now sitting on 314.27M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Celsius Holdings’s stock is considered to be oversold (<=20).

Celsius Holdings’s Stock Yearly Top and Bottom Value

Celsius Holdings’s stock is valued at $99.80 at 17:33 EST, under its 52-week high of $110.22 and way above its 52-week low of $38.31.

Celsius Holdings’s Moving Average

Celsius Holdings’s worth is way above its 50-day moving average of $69.06 and way higher than its 200-day moving average of $65.26.

More news about Celsius Holdings.

7. Roku (ROKU) – 9.45%

Roku, Inc., along with its affiliates, operate a streaming TV platform. It operates under two distinct segments: Platform and Player. The company’s platform allows people to search for and find different TV shows and movies, live music and news. The company has 36.9million active accounts as of December 31, 2019. The company also offers advertising products such as videos ads, brand sponsorships and audience development campaigns. It manufactures and licenses TVs and subscription billing services. The company also offers accessories and streaming media players under the Roku name. It sells brand-name channel buttons for remote controls. The company sells its products through distributors and retailers as well as direct to its customers via its website. It has offices in several countries, including the United States, Canada and Mexico. It was established in Los Gatos in California in 2002.

NASDAQ ended the session with Roku jumping 9.45% to $71.71 on Monday while NASDAQ slid 0.18% to $12,368.98.

Volume

Today’s last reported volume for Roku is 25055600 which is 191.15% above its average volume of 8605670.

Roku’s last close was $65.52, 86.65% under its 52-week high of $490.76.

The company’s growth estimates for the current quarter and the next is a negative 230.8% and a negative 212.5%, respectively.

Roku’s Revenue

Year-on-year quarterly revenue growth grew by 27.8%, now sitting on 2.92B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Roku’s stock is considered to be overbought (>=80).

Roku’s Stock Yearly Top and Bottom Value

Roku’s stock is valued at $71.71 at 17:33 EST, under its 52-week low of $72.63.

Roku’s Moving Average

Roku’s value is way under its 50-day moving average of $89.43 and way under its 200-day moving average of $163.97.

Previous days news about Roku

  • Stocks making the biggest moves in the premarket: Amazon, Roku, Intel, Chevron and more. According to CNBC on Friday, 29 July, "Roku (ROKU) – Roku stock was slammed 23.2% in premarket trading after it reported a larger-than-expected quarterly loss and its revenue missed estimates as well. "
  • Roku earnings: ROKU stock gets slammed in premarket after major miss. According to FXStreet on Friday, 29 July, "While Wall Street had been expecting $902 million in revenue for Q3, Roku management said to instead expect $700 million."

More news about Roku.

8. Groupon (GRPN) – 8.49%

Groupon, Inc. offers goods and services at discounted prices in North America as well as internationally through its online marketplaces. Groupon offers deals across a variety of categories including: events, activities, health, beauty and wellness, food and drink, home and garden, automotive, discounted rates and market rates on hotel and airfare as well as package and deal deals on many product lines such as electronics and sporting goods, jewelry and toys. Customers can access its deals through websites, search engines, mobile apps and mobile. These allow consumers to view, buy, manage and redeem offers on mobile phones; email and push notifications, affiliate channels, social and display ads; offline marketing; and to make purchases. The original name of the company was ThePoint.com, Inc., but it changed its name in October 2008 to Groupon, Inc. Groupon, Inc. was established in 2008. It is located in Chicago, Illinois.

NASDAQ ended the session with Groupon rising 8.49% to $11.50 on Monday while NASDAQ fell 0.18% to $12,368.98.

Volume

Today’s last reported volume for Groupon is 661577 which is 38.86% below its average volume of 1082120.

Groupon’s last close was $10.60, 74.56% under its 52-week high of $41.66.

Groupon’s Sales

Groupon’s sales growth is a negative 38.1% for the present quarter and a decline by 16.3% for the next. The company’s growth estimates for the current quarter and the next is a negative 172.7% and a negative 13.2%, respectively.

Groupon’s Revenue

Year-on-year quarterly revenue growth declined by 34.9%, now sitting on 967.11M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Groupon’s stock is considered to be oversold (<=20).

Groupon’s Stock Yearly Top and Bottom Value

Groupon’s stock is valued at $11.50 at 17:33 EST, way below its 52-week high of $41.66 and way higher than its 52-week low of $8.78.

Groupon’s Moving Average

Groupon’s worth is way below its 50-day moving average of $13.18 and way under its 200-day moving average of $19.89.

More news about Groupon.

9. Sarepta Therapeutics (SRPT) – 8.17%

Sarepta Therapeutics, Inc. is a biopharmaceutical company at the commercial stage. It focuses on developing RNA-targeted therapeutics, genetic therapy, and other gene therapeutic modalities to treat rare diseases. EXONDYS 51 is an injection that treats duchenne muscular disorder (DMD), in patients with a confirmed DMD mutation that allows for exon 51 to skip. VYONDYS53 is used to treat DMD in patients with a DMD mutation that permits exon 53 to skip. AMONDYS 45 is a candidate product that utilizes phosphorodiamidate-morpholino-oligomer (PMO), chemistry, and exon-skipping technology. F. Hoffman-La Roche Ltd, Nationwide Children’s Hospital, Lysogene and Genethon have collaborated with the company. The company also has an option and research agreement with Codiak BioSciences, Inc. for the development of engineered exosome therapies to deliver gene therapy, gene edit, and other RNA technologies to neuromuscular disorders; as well as a collaboration with Genevant Sciences to research lipid nanoparticle-based genetic editing therapeutics. Sarepta Therapeutics, Inc., was founded in 1980. It is located in Cambridge, Massachusetts.

NASDAQ ended the session with Sarepta Therapeutics rising 8.17% to $92.95 on Monday, after three successive sessions in a row of gains. NASDAQ slid 0.18% to $12,368.98, after three sequential sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Sarepta Therapeutics is 3663800 which is 335.49% above its average volume of 841306.

Sarepta Therapeutics’s last close was $92.95, 8.19% below its 52-week high of $101.24.

The company’s growth estimates for the current quarter and the next is a negative 15.7% and a negative 66.7%, respectively.

Sarepta Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 38.8%, now sitting on 701.89M for the twelve trailing months.

Sarepta Therapeutics’s Stock Yearly Top and Bottom Value

Sarepta Therapeutics’s stock is valued at $92.95 at 17:34 EST, under its 52-week high of $101.24 and way higher than its 52-week low of $61.28.

Sarepta Therapeutics’s Moving Average

Sarepta Therapeutics’s value is way above its 50-day moving average of $75.37 and way above its 200-day moving average of $78.32.

More news about Sarepta Therapeutics.

10. Nautilus (NLS) – 7.47%

NYSE ended the session with Nautilus rising 7.47% to $1.87 on Monday while NYSE dropped 0.27% to $15,286.01.

Volume

Today’s last reported volume for Nautilus is 498817 which is 42.86% below its average volume of 873019.

Nautilus’s last close was $1.74, 89.56% below its 52-week high of $16.67.

Nautilus’s Sales

Nautilus’s sales growth is a negative 41% for the ongoing quarter and a decline by 31.7% for the next. The company’s growth estimates for the current quarter and the next is a negative 161.7% and a negative 172.1%, respectively.

Nautilus’s Revenue

Year-on-year quarterly revenue growth declined by 22.2%, now sitting on 664.91M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Nautilus’s stock is considered to be overbought (>=80).

Nautilus’s Stock Yearly Top and Bottom Value

Nautilus’s stock is valued at $1.87 at 17:34 EST, way below its 52-week high of $16.67 and way higher than its 52-week low of $1.70.

Nautilus’s Moving Average

Nautilus’s value is way under its 50-day moving average of $2.46 and way under its 200-day moving average of $5.61.

More news about Nautilus.

Most Active Losers Today

1. Tonix Pharmaceuticals Holding Corp. (TNXP) – -10.16%

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment. Its preclinical pipeline includes TNX-1600 for PTSD, depression, and attention deficit hyperactivity disorder; TNX-1700 for gastric and pancreatic cancers; TNX-701 for radioprotection; TNX-1200, a smallpox vaccine; TNX-1500, a monoclonal antibody anti-CD40-L for organ transplant rejection autoimmunity; and TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome. It also develops TNX-2100, a COVID-19 skin test. It has collaboration agreements with Southern Research Institute and the University of Alberta; and Massachusetts General Hospital. The company was incorporated in 2007 and is headquartered in Chatham, New Jersey.

NASDAQ ended the session with Tonix Pharmaceuticals Holding Corp. falling 10.16% to $1.68 on Monday while NASDAQ dropped 0.18% to $12,368.98.

Volume

Today’s last reported volume for Tonix Pharmaceuticals Holding Corp. is 36831400 which is 286.47% above its average volume of 9529990.

Tonix Pharmaceuticals Holding Corp.’s last close was $1.68, 93.6% below its 52-week high of $26.24.

The company’s growth estimates for the current quarter and the next is 35.7% and 6.9%, respectively.

Tonix Pharmaceuticals Holding Corp.’s Stock Yearly Top and Bottom Value

Tonix Pharmaceuticals Holding Corp.’s stock is valued at $1.68 at 17:35 EST, way under its 52-week high of $26.24 and way higher than its 52-week low of $1.19.

Tonix Pharmaceuticals Holding Corp.’s Moving Average

Tonix Pharmaceuticals Holding Corp.’s value is below its 50-day moving average of $1.85 and way under its 200-day moving average of $8.06.

More news about Tonix Pharmaceuticals Holding Corp..

2. 21Vianet Group (VNET) – -8.04%

21Vianet Group, Inc., an investment holding company, provides hosting and related services to Internet companies, government entities, blue-chip enterprises, and small-to mid-sized enterprises in the People's Republic of China. It offers hosting and related services to house servers and networking equipment in its data centers, and connects them through a data transmission network. The company's hosting and related services include managed hosting services that offer data center space to house its customers' servers and networking equipment, and provide tailored server administration services; and interconnectivity services that enable customers to connect their servers with internet backbones and other networks through its border gateway protocol network or single-line, dual-line, or multiple-line network. Its hosting and related services also comprise cloud services that enable businesses to run their applications over the internet using its IT infrastructure; virtual private network services; hybrid IT Services, which provide customers with a complete package of infrastructure service offerings; and other value-added services, such as firewall, server load balancing, data backup and recovery, data center management, server management, and backup server services. In addition, the company provides traffic charts and analysis, gateway monitoring for servers, domain name system setup, defense mechanism against distributed denial of service attacks, basic setting of switches and routers, and virus protections; and managed network service. As of December 31, 2020, it operated 32 self-built data centers housing 49,876 cabinets and 52 partnered data centers housing with 3,677 cabinets. It has a strategic partnership with Microsoft Corporation. 21Vianet Group, Inc. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with 21Vianet Group dropping 8.04% to $4.75 on Monday while NASDAQ slid 0.18% to $12,368.98.

Volume

Today’s last reported volume for 21Vianet Group is 1192170 which is 21.23% below its average volume of 1513630.

21Vianet Group’s last close was $5.16, 77.48% under its 52-week high of $22.91.

21Vianet Group’s Sales

21Vianet Group’s sales growth is 9.4% for the current quarter and 12.1% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 225% and a negative 94.1%, respectively.

21Vianet Group’s Revenue

Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 6.45B for the twelve trailing months.

21Vianet Group’s Stock Yearly Top and Bottom Value

21Vianet Group’s stock is valued at $4.75 at 17:35 EST, way under its 52-week high of $22.91 and way higher than its 52-week low of $3.51.

21Vianet Group’s Moving Average

21Vianet Group’s worth is way below its 50-day moving average of $5.54 and way under its 200-day moving average of $8.42.

More news about 21Vianet Group.

3. Royal Caribbean Cruises (RCL) – -7.85%

Royal Caribbean Group operates as a cruise company. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, Azamara Club Cruises, and Silversea Cruises brands. The Royal Caribbean International brand provides itineraries to destinations worldwide, including Alaska, Asia, Australia, Bahamas, Bermuda, Canada, the Caribbean, Europe, the Panama Canal, and New Zealand with cruise lengths that range from 2 to 19 nights. The Celebrity Cruises brand offers itineraries to destinations, such as Alaska, Asia, Australia, Bermuda, Canada, the Caribbean, Europe, the Galapagos Islands, Hawaii, India, New Zealand, the Panama Canal, and South America with cruise lengths ranging from 2 to 19 nights. The Azamara Club Cruises brand offers cruise itineraries to destinations, including Asia, Australia/New Zealand, Northern and Western Europe, the Mediterranean, Cuba, and South America with cruise lengths ranging from 3 to 26 nights. The Silversea Cruises brand provides itineraries to destinations, including the Galapagos Islands, Antarctica, and the Arctic with cruise lengths ranging from 6 to 25 nights. As of December 31, 2019, the company operated 61 ships and had 17 ships on order. The company was formerly known as Royal Caribbean Cruises Ltd. Royal Caribbean Group was founded in 1968 and is headquartered in Miami, Florida.

NYSE ended the session with Royal Caribbean Cruises dropping 7.85% to $35.67 on Monday, after five sequential sessions in a row of gains. NYSE dropped 0.27% to $15,286.01, after three successive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Royal Caribbean Cruises is 21260200 which is 244.01% above its average volume of 6180050.

Royal Caribbean Cruises’s last close was $38.71, 60.99% below its 52-week high of $99.24.

Royal Caribbean Cruises’s Sales

Royal Caribbean Cruises’s sales growth is a negative 1930.2% for the ongoing quarter and 3097.1% for the next. The company’s growth estimates for the present quarter and the next is 25.4% and 33.9%, respectively.

Royal Caribbean Cruises’s Revenue

Year-on-year quarterly revenue growth declined by 97.9%, now sitting on 218.07M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Royal Caribbean Cruises’s stock is considered to be oversold (<=20).

Royal Caribbean Cruises’s Stock Yearly Top and Bottom Value

Royal Caribbean Cruises’s stock is valued at $35.67 at 17:35 EST, way below its 52-week low of $64.20.

Royal Caribbean Cruises’s Moving Average

Royal Caribbean Cruises’s value is way below its 50-day moving average of $82.92 and way below its 200-day moving average of $84.22.

More news about Royal Caribbean Cruises.

4. Ultra Clean Holdings (UCTT) – -6.9%

Ultra Clean Holdings, Inc. designs, engineers, and manufactures production tools, modules, and subsystems for the semiconductor and display capital equipment markets in the United States and internationally. The company provides subsystems, such as wafer cleaning modules; chemical delivery modules that deliver gases and reactive chemicals in a liquid or gaseous form from a centralized subsystem to the reaction chamber; frame assemblies; process modules, a subsystems of semiconductor manufacturing tools that process integrated circuits onto wafers; and top-plate assemblies. It also offers various industrial and automation production equipment products; gas delivery systems, which include one or more gas lines, such as weldments, filters, mass flow controllers, regulators, pressure transducers and valves, component heaters, and an integrated electronic and/or pneumatic control system; fluid delivery systems consists of one or more chemical delivery units, including PFA tubing, filters, flow controllers, regulators, component heaters, and an integrated electronic and/or pneumatic control system; precision robotic systems that are used when accurate controlled motion is required; and other high level assemblies. In addition, the company provides tool chamber parts cleaning and coating services; micro-contamination analysis services for tool parts, wafers and depositions, chemicals, cleanroom materials, deionized water, and airborne molecular contamination; and analytical verification services for process tool chamber part cleaning. It primarily serves original equipment manufacturing customers in the semiconductor capital equipment and semiconductor integrated device manufacturing industries, as well as display, consumer, medical, energy, industrial, and research equipment industries. Ultra Clean Holdings, Inc. was founded in 1991 and is headquartered in Hayward, California.

NASDAQ ended the session with Ultra Clean Holdings dropping 6.9% to $33.60 on Monday while NASDAQ dropped 0.18% to $12,368.98.

Volume

Today’s last reported volume for Ultra Clean Holdings is 941928 which is 144.48% above its average volume of 385272.

Ultra Clean Holdings’s last close was $33.60, 44.77% below its 52-week high of $60.84.

Ultra Clean Holdings’s Sales

Ultra Clean Holdings’s sales growth is 14.7% for the ongoing quarter and 15.9% for the next. The company’s growth estimates for the ongoing quarter and the next is 4% and 15%, respectively.

Ultra Clean Holdings’s Revenue

Year-on-year quarterly revenue growth grew by 35.1%, now sitting on 2.25B for the twelve trailing months.

Ultra Clean Holdings’s Stock Yearly Top and Bottom Value

Ultra Clean Holdings’s stock is valued at $33.60 at 17:35 EST, way under its 52-week high of $60.84 and way higher than its 52-week low of $26.00.

Ultra Clean Holdings’s Moving Average

Ultra Clean Holdings’s worth is higher than its 50-day moving average of $31.31 and way below its 200-day moving average of $43.01.

More news about Ultra Clean Holdings.

5. Travelzoo (TZOO) – -6.43%

Travelzoo, an Internet media company, provides travel, entertainment, and local deals from travel and entertainment companies, and local businesses in the Asia Pacific, Europe, and North America. Its publications and products include Travelzoo Website; Travelzoo iPhone and Android apps; Travelzoo Top 20 email newsletter; and Newsflash email alert service. The company also operates the Travelzoo Network, a network of third-party Websites that list travel deals published by the company; and Local Deals and Getaway listings, which allow its members to purchase vouchers for deals from local businesses, such as spas, hotels, and restaurants. It serves airlines, hotels, cruise lines, vacations packagers, tour operators, destinations, car rental companies, travel agents, theater and performing arts groups, restaurants, spas, and activity companies. Travelzoo Inc. was founded in 1998 and is headquartered in New York, New York.

NASDAQ ended the session with Travelzoo sliding 6.43% to $5.09 on Monday, after four successive sessions in a row of losses. NASDAQ slid 0.18% to $12,368.98, after three sequential sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Volume

Today’s last reported volume for Travelzoo is 197083 which is 107.26% above its average volume of 95088.

Travelzoo’s last close was $5.09, 65.95% under its 52-week high of $14.95.

Travelzoo’s Revenue

Year-on-year quarterly revenue growth declined by 7.3%, now sitting on 65.49M for the twelve trailing months.

Travelzoo’s Stock Yearly Top and Bottom Value

Travelzoo’s stock is valued at $5.09 at 17:35 EST, way under its 52-week high of $14.95 and above its 52-week low of $5.05.

Travelzoo’s Moving Average

Travelzoo’s worth is way under its 50-day moving average of $6.41 and way below its 200-day moving average of $8.21.

More news about Travelzoo.

6. TG Therapeutics (TGTX) – -6.26%

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.

NASDAQ ended the session with TG Therapeutics dropping 6.26% to $5.99 on Monday while NASDAQ fell 0.18% to $12,368.98.

Volume

Today’s last reported volume for TG Therapeutics is 2205400 which is 31.07% below its average volume of 3199800.

TG Therapeutics’s last close was $5.99, 83.33% under its 52-week high of $35.94.

The company’s growth estimates for the ongoing quarter and the next is 13.6% and 27.7%, respectively.

TG Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 154.2%, now sitting on 7.91M for the twelve trailing months.

TG Therapeutics’s Stock Yearly Top and Bottom Value

TG Therapeutics’s stock is valued at $5.99 at 17:35 EST, way under its 52-week high of $35.94 and way higher than its 52-week low of $3.48.

TG Therapeutics’s Moving Average

TG Therapeutics’s value is way higher than its 50-day moving average of $5.12 and way below its 200-day moving average of $13.14.

More news about TG Therapeutics.

7. Canaan (CAN) – -6.11%

Canaan Inc. engages in the research, design, and sale of integrated circuit (IC) final system products by integrating IC products for bitcoin mining and related components primarily in the People's Republic of China. It is also involved in the assembly of system products; and supply chain and distribution of system products. The company has a strategic cooperation with Northern Data AG in the areas of artificial intelligence development, blockchain technology, and datacenter operations. The company was founded in 2013 and is based in Hangzhou, the People's Republic of China.

NASDAQ ended the session with Canaan dropping 6.11% to $3.69 on Monday while NASDAQ dropped 0.18% to $12,368.98.

Volume

Today’s last reported volume for Canaan is 2474920 which is 26.24% below its average volume of 3355770.

Canaan’s last close was $3.93, 64.88% below its 52-week high of $11.19.

Canaan’s Revenue

Year-on-year quarterly revenue growth grew by 5611.9%, now sitting on 4.99B for the twelve trailing months.

Canaan’s Stock Yearly Top and Bottom Value

Canaan’s stock is valued at $3.69 at 17:35 EST, way below its 52-week high of $11.19 and way above its 52-week low of $2.56.

Canaan’s Moving Average

Canaan’s worth is above its 50-day moving average of $3.61 and way under its 200-day moving average of $5.26.

More news about Canaan.

8. Tilray (TLRY) – -6.03%

NASDAQ ended the session with Tilray dropping 6.03% to $3.43 on Monday while NASDAQ dropped 0.18% to $12,368.98.

Volume

Today’s last reported volume for Tilray is 18372100 which is 26.7% below its average volume of 25065500.

Tilray’s last close was $3.65, 90.53% under its 52-week high of $38.53.

The company’s growth estimates for the present quarter and the next is a negative 250% and a negative 200%, respectively.

Tilray’s Revenue

Year-on-year quarterly revenue growth grew by 8.5%, now sitting on 513.08M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Tilray’s stock is considered to be oversold (<=20).

Tilray’s Stock Yearly Top and Bottom Value

Tilray’s stock is valued at $3.43 at 17:35 EST, way below its 52-week low of $7.93.

Tilray’s Moving Average

Tilray’s worth is way under its 50-day moving average of $10.73 and way below its 200-day moving average of $14.96.

Previous days news about Tilray

  • Cannabis company tilray downgraded to sell by benchmark. According to MarketWatch on Friday, 29 July, "Benchmark analyst Mike Hickey on Friday downgraded Tilray Brands Inc. to sell and set a price target of $3 a share after the cannabis company disclosed retail market share losses in Canada to 8.3% in its fiscal fourth quarter, from 10.2% in the third quarter and 12.8% in the second quarter. ", "But Hickey said he remains cautious that "newly announced profit growth primarily reflects newly announced revenue and cost synergies and are potentially masking continued deterioration from its core Canadian cannabis business." Shares of Tilray are down 48.1% in 2022 compared to a loss of 56% by the Cannabis ETF and a drop of 22.3% by the Nasdaq ."

More news about Tilray.

9. Trevena (TRVN) – -5.67%

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

NASDAQ ended the session with Trevena falling 5.67% to $0.25 on Monday, after five sequential sessions in a row of losses. NASDAQ dropped 0.18% to $12,368.98, after three consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Volume

Today’s last reported volume for Trevena is 1740210 which is 13.8% below its average volume of 2018900.

Trevena’s last close was $0.25, 83.9% below its 52-week high of $1.54.

Trevena’s Sales

Trevena’s sales growth is a negative 74.5% for the present quarter and 198.3% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 11.1% and a negative 25%, respectively.

Trevena’s Revenue

Year-on-year quarterly revenue growth declined by 90.4%, now sitting on 378k for the twelve trailing months.

Trevena’s Stock Yearly Top and Bottom Value

Trevena’s stock is valued at $0.25 at 17:35 EST, way under its 52-week high of $1.54 and way above its 52-week low of $0.18.

Trevena’s Moving Average

Trevena’s worth is way below its 50-day moving average of $0.35 and way under its 200-day moving average of $0.53.

More news about Trevena.

10. Marathon (MARA) – -5.6%

Marathon Patent Group, Inc. operates as a digital asset technology company that mines cryptocurrencies. It owns cryptocurrency mining machines and a data center to mine digital assets in Quebec, Canada. The company was formerly known as American Strategic Minerals Corporation and changed its name to Marathon Patent Group, Inc. in February 2013. Marathon Patent Group, Inc. was founded in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon falling 5.6% to $12.26 on Monday, following the last session’s downward trend. NASDAQ slid 0.18% to $12,368.98, after three successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Volume

Today’s last reported volume for Marathon is 20267700 which is 18.64% above its average volume of 17083100.

Marathon’s last close was $12.99, 84.43% below its 52-week high of $83.45.

Marathon’s Sales

Marathon’s sales growth is 286.1% for the ongoing quarter and 236.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 137.6% and 377.3%, respectively.

Marathon’s Revenue

Year-on-year quarterly revenue growth grew by 2180.3%, now sitting on 150.46M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Marathon’s stock is considered to be oversold (<=20).

Marathon’s Stock Yearly Top and Bottom Value

Marathon’s stock is valued at $12.26 at 17:35 EST, way under its 52-week high of $83.45 and way higher than its 52-week low of $5.20.

Marathon’s Moving Average

Marathon’s value is way higher than its 50-day moving average of $8.75 and way below its 200-day moving average of $26.96.

More news about Marathon.

Stay up to date with our winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here